Tumor lysis syndrome (TLS) in acute myeloid leukemia (AML) patients treated with azacitidine (AZA) and venetoclax (VEN).
Joanna Q. Huang(University of Colorado Hospital), Jeff Kaiser, Emmeline C. Academia(University of Colorado Hospital), Daniel A. Pollyea(University of Colorado Denver), Jonathan A. Gutman(University of Colorado Denver), Andrew Hammes(Colorado School of Public Health), Cindy L. O’Bryant(University of Montana), Stephanie Chase(Eastern Oregon University)
Cited by 5
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655
Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells
|Cancer Cell|2018|565